EIGER BIOPHARMACEUTICALS INC (EIGR) Stock Price & Overview
NASDAQ:EIGR • US28249U2042
Current stock price
The current stock price of EIGR is 1.725 USD. Today EIGR is down by -9.21%. In the past month the price decreased by -70.76%. In the past year, price decreased by -94.72%.
EIGR Key Statistics
- Market Cap
- 2.552M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -10.49
- Dividend Yield
- N/A
EIGR Stock Performance
EIGR Stock Chart
EIGR Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to EIGR. When comparing the yearly performance of all stocks, EIGR is a bad performer in the overall market: 99.69% of all stocks are doing better.
EIGR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EIGR. EIGR has a bad profitability rating. Also its financial health evaluation is rather negative.
EIGR Earnings
EIGR Forecast & Estimates
8 analysts have analysed EIGR and the average price target is 91.8 USD. This implies a price increase of 5221.74% is expected in the next year compared to the current price of 1.725.
For the next year, analysts expect an EPS growth of 68.29% and a revenue growth 37.05% for EIGR
EIGR Groups
Sector & Classification
EIGR Financial Highlights
Over the last trailing twelve months EIGR reported a non-GAAP Earnings per Share(EPS) of -10.49. The EPS decreased by -348.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -193.08% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EIGR Ownership
EIGR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.9 | 368.381B | ||
| AMGN | AMGEN INC | 15.33 | 189.472B | ||
| GILD | GILEAD SCIENCES INC | 15.96 | 175.4B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.63 | 114.717B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.77 | 78.668B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.7 | 41.749B | ||
| INSM | INSMED INC | N/A | 30.759B | ||
| NTRA | NATERA INC | N/A | 28.033B | ||
| BIIB | BIOGEN INC | 11.41 | 26.756B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.64 | 23.245B | ||
| MRNA | MODERNA INC | N/A | 20.695B | ||
| EXAS | EXACT SCIENCES CORP | 341.89 | 19.805B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.443B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EIGR
Company Profile
Eiger BioPharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Palo Alto, California and currently employs 56 full-time employees. The company went IPO on 2014-01-30. Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.
Company Info
IPO: 2014-01-30
EIGER BIOPHARMACEUTICALS INC
2155 Park Blvd
Palo Alto CALIFORNIA 94306 US
CEO: David A. Cory
Employees: 56
Phone: 16502799845
EIGER BIOPHARMACEUTICALS INC / EIGR FAQ
Can you describe the business of EIGER BIOPHARMACEUTICALS INC?
Eiger BioPharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Palo Alto, California and currently employs 56 full-time employees. The company went IPO on 2014-01-30. Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.
Can you provide the latest stock price for EIGER BIOPHARMACEUTICALS INC?
The current stock price of EIGR is 1.725 USD. The price decreased by -9.21% in the last trading session.
Does EIGR stock pay dividends?
EIGR does not pay a dividend.
What is the ChartMill technical and fundamental rating of EIGR stock?
EIGR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists EIGR stock?
EIGR stock is listed on the Nasdaq exchange.
What is the market capitalization of EIGR stock?
EIGER BIOPHARMACEUTICALS INC (EIGR) has a market capitalization of 2.55M USD. This makes EIGR a Nano Cap stock.
Can you provide the ownership details for EIGR stock?
You can find the ownership structure of EIGER BIOPHARMACEUTICALS INC (EIGR) on the Ownership tab.